Pacific Edge Limited · NZX:PEB
Pacific Edge — Investor Presentation (May 2015)
18 slides from Pacific Edge's investor presentation, May 28, 2015
Slide 1: Capital Raise Presentation
Pacific Edge Limited Capital Raise Presentation 28 May 2015 First NZ Capital
Slide 2: Important Notice
Important Notice This capital raise presentation has been prepared by Pacific Edge Limited (Pacific Edge). This presentation has been prepared in relation to the pro rata renounceable rights offer of new shares in Pacific Edge (New Shares) to be made to: • Eligible institutional shareholders of Paci
Slide 3: Important Notice
Important Notice Investment risk An investment in securities in Pacific Edge is subject to investment and other known and unknown risks, some of which are beyond the control of Pacific Edge. Pacific Edge does not guarantee any particular rate of return or the performance of Pacific Edge. Not an offe
Slide 4: Capital Raising Summary
Capital Raising Summary
Slide 5: Details of the Capital Raise
Pacific Edge | Details of the Capital Raise Pacific Edge is seeking to raise NZ$35.3m via a renounceable rights The rights issue will provide Pacific Edge with the funding to: offer made to eligible • Expand its sales force in the US from 12 to 18 to service 19 major metro regions in the US investor
Slide 6: Company Update
Company Update
Slide 7: Cxbladder: A new class of detection and management tests for urothelial carcinoma
Cxbladder | A new class of detection and management tests for urothelial carcinoma Pacific Edge’s suite of Cxbladder product suite Current standard of care products, which are designed to be sequential and complementary, Cxbladder Cxbladder Cxbladder Cxbladder Cytology Cystoscopy Detect Triage Monit
Slide 8: Key drivers of revenue growth are regulatory, reimbursement and adoption
Pacific Edge | Key drivers of revenue growth for PEB are regulatory, reimbursement and adoption Pacific Edge is gaining Regulatory approvals in place, including in the US – the world’s largest healthcare market traction with key • CLIA1 certification received for both the US and NZ laboratory custom
Slide 9: Cxbladder: Lab throughput data is a measure of adoption
Cxbladder | Lab throughput data is a measure of adoption Lab throughput is the Lab throughput showing significant improvements strongest tangible measure of adoption for Pacific Edge Throughput has 140% continued to improve substantially throughout the first full year of trading in the 278% US with
Slide 10: Cxbladder: the US represents a significant opportunity
Cxbladder | the US represents a significant opportunity The US market is Pacific Edge is focused on building sales in the US, the world’s largest healthcare market with seven million people significant with the annually presenting with hematuria potential for millions of Cxbladder test opportunities
Slide 11: South East Asia commercial growth opportunity currently being scoped
Pacific Edge | South East Asia commercial growth opportunity currently being scoped South East Asia Pacific Edge will complete the evaluation of developing an entry point to South East Asia for Cxbladder products represents a new and through Singapore, with this market initially serviced by Pacific
Slide 12: Cxbladder Monitor and Cxbladder Predict
Pacific Edge | Cxbladder Monitor and Cxbladder Predict Pacific Edge will use a Cxbladder Monitor portion of the proceeds • Bladder cancer has a high recurrence rate 50-70% with a large number of tumour progressions1 from the equity raise to complete the • Under traditional bladder cancer follow-up e
Slide 13: Objectives for 2015 / 2016
The opportunity | Objectives for 2015 / 2016 Escalation of growth in the US Current direct sales force of 12 account executives Increase to 18 sales executives covering 19 major metropolitan regions in the US Gain commercial access to the Veterans Administration (VA) and Centers for Medicare and Med
Slide 14: Offer Details
Offer Details
Slide 15: Capital raising overview
Pacific Edge | Capital raising overview Entitlement Offer Entitlement ratio 2 new shares for every 11 existing shares Maximum New Shares to be issued 57,930,167 Application price NZ$0.61 Offer discount 13.2% to TERP1 Total equity to be raised under the Entitlement Offer $35.3m New Shares issued on c
Slide 16: Use of Proceeds: How Pacific Edge will allocate the new capital
Use of Proceeds | How Pacific Edge will allocate the new capital A portion of the capital Specific cash outflows FY16 FY17 Description raising proceeds is earmarked for implementation of specific Implementation of the increased sales initiatives as set out on Grow the US business $3.7m $4.2m force a
Slide 17: Timetable
Pacific Edge | Timetable Key Dates Entitlement Offer announced Thursday, 28 May 2015 Rights trading commences Friday, 5 June 2015 Record Date for Entitlement Offer Tuesday, 9 June 2015 Expected despatch of Offer Document and Entitlement and Thursday, 11 June 2015 Acceptance Forms Entitlement Offer o
Slide 18: www.pacificedge.co.nz www.cxbladder.com www.pacificedgedx.com
www.pacificedge.co.nz www.cxbladder.com www.pacificedgedx.com